-
公开(公告)号：EP2684571B1
公开(公告)日：2021-05-26
申请号：EP13180503.8
申请日：2006-11-09
-
公开(公告)号：EP2568991B3
公开(公告)日：2018-11-28
申请号：EP11781272.7
申请日：2011-05-12
申请人： ABT Holding Company
发明人： MAYS, Robert, W.
IPC分类号： C12N5/074 , G01N33/483 , A61K35/28
CPC分类号： A61K35/28 , A61K35/545 , C12N5/0607 , G01N33/5047 , G01N33/505 , G01N33/6893 , G01N2333/5406 , G01N2333/5412 , G01N2333/5428 , G01N2333/545 , G01N2333/70514 , G01N2333/70517 , G01N2500/00 , G01N2800/24 , G01N2800/52
摘要： The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1β, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.
-
公开(公告)号：EP2539439B1
公开(公告)日：2018-10-17
申请号：EP11747958.4
申请日：2011-02-23
申请人： ABT Holding Company
CPC分类号： A61K35/545 , G01N33/5008
摘要： The invention provides methods for treating pathological conditions that can be improved by providing angiogenesis. The invention is generally directed to provide angiogenesis by administering cells that express and/or secrete one or more pro-angiogenic factors. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete one or more pro-angiogenic factors. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of expression and/or secretion of one or more pro-angiogenic factors.
-
公开(公告)号：EP2456860B1
公开(公告)日：2018-09-05
申请号：EP10802822.6
申请日：2010-07-21
申请人： ABT Holding Company
发明人： VAN'T HOF, Wouter
CPC分类号： C12N5/0634 , A61K35/545 , C12N5/0607 , C12N2502/03 , C12N2502/11 , G01N33/5073
摘要： The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.
-
5.发明公开
公开(公告)号：EP2938345A2
公开(公告)日：2015-11-04
申请号：EP13864916.5
申请日：2013-12-23
申请人： ABT Holding Company
发明人： ROBARGE, Mike , HARRINGTON, John , GERRISH, David , MECOM, John
IPC分类号： A61K31/55
CPC分类号： C07D223/32 , C07D401/04 , C07D417/04 , C07D491/048 , C07D491/052
摘要： The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are benzazepine compounds. These compounds are serotonin receptor (5-HT
2c ) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT
2c ) is desired (e.g. addiction, anxiety, depression, obesity, and others).-
公开(公告)号：EP2456860A1
公开(公告)日：2012-05-30
申请号：EP10802822.6
申请日：2010-07-21
申请人： ABT Holding Company
发明人： VAN'T HOF, Wouter
IPC分类号： C12N5/071
CPC分类号： C12N5/0634 , A61K35/545 , C12N5/0607 , C12N2502/03 , C12N2502/11 , G01N33/5073
摘要： The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.
-
7.发明授权EXPRESSION OF ENDOGENOUS GENES BY NON-HOMOLOGOUS RECOMBINATION OF A VECTOR CONSTRUCT WITH CELLULAR DNA 有权内源基因的表达通过同源重组的载体与细胞DNA构建
公开(公告)号：EP1017803B1
公开(公告)日：2010-06-16
申请号：EP98949508.0
申请日：1998-09-25
申请人： ABT Holding Company
发明人： HARRINGTON, John, J.
CPC分类号： C12N15/90 , A61K48/00 , C12N15/67 , C12N15/85 , C12N2840/20 , C12N2840/44
-
-
公开(公告)号：EP1951294B1
公开(公告)日：2019-12-25
申请号：EP06837336.4
申请日：2006-11-09
-
公开(公告)号：EP2568991A1
公开(公告)日：2013-03-20
申请号：EP11781272.7
申请日：2011-05-12
申请人： ABT Holding Company
发明人： MAYS, Robert, W.
IPC分类号： A61K35/12
CPC分类号： A61K35/28 , A61K35/545 , C12N5/0607 , G01N33/5047 , G01N33/505 , G01N33/6893 , G01N2333/5406 , G01N2333/5412 , G01N2333/5428 , G01N2333/545 , G01N2333/70514 , G01N2333/70517 , G01N2500/00 , G01N2800/24 , G01N2800/52
摘要： The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1β, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.02 秒)
